Inventor · disambiguated record
Ignacio Anegon
Also filed as: ANEGON IGNACIO
10 granted patents·9 pending applications·4 citations·filing 2015–2024
80Inventor score
Files withINST NAT SANTE RECH MED15ABOLERIS PHARMA1INSERM (INSTITUT NAT DE LA SANTÉ ET DE LA RECH MÉDICALE1INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECH MÉDICALE)1INSERM INSTITUTE NATIONAL DE LA SANTE ET DE LA RECH MEDICALE1
Top patents by PatentIndex Score
19 records- 0180US11090362B2Pharmaceutical composition comprising IL-34 and a mTOR inhibitorINST NAT SANTE RECH MED·Filed 2018·Granted Aug 17, 2021·2 cites·4 claims
- 0273US12083163B2Isolated interleukin-34 polypeptide for use in preventing transplant rejection and treating autoimmune diseasesINST NAT SANTE RECH MED·Filed 2021·Granted Sep 10, 2024·0 cites·11 claims
- 0371US2025122300A1Anti-human cd45rc antibodies and uses thereofINST NAT SANTE RECH MED·Filed 2024·Application pending·0 cites
- 0463US12146159B2Methods for obtaining regulatory t cells and uses thereofINST NAT SANTE RECH MED·Filed 2020·Granted Nov 19, 2024·0 cites·12 claims
- 0561US10137181B2Isolated donor MHC-derived peptide and uses thereofINST NAT SANTE RECH MED·Filed 2015·Granted Nov 27, 2018·1 cites·10 claims
- 0661US10105425B2Isolated donor MHC-derived peptide and uses thereofINST NAT SANTE RECH MED·Filed 2015·Granted Oct 23, 2018·1 cites·12 claims
- 0759US2025281535A1Anti-human cd45rc binding domains and uses thereofABOLERIS PHARMA·Filed 2022·Application pending·0 cites
- 0856US12168694B2Anti-human CD45RC antibodies and uses thereofINST NAT SANTE RECH MED·Filed 2019·Granted Dec 17, 2024·0 cites·20 claims
- 0956US10724001B2Methods for obtaining regulatory T cells and uses thereofINST NAT SANTE RECH MED·Filed 2016·Granted Jul 28, 2020·0 cites·12 claims
- 1052US2023147657A1Chimeric antigen receptor specific for human cd45rc and uses thereofINST NAT SANTE RECH MED·Filed 2021·Application pending·0 cites
- 1149US12466866B2Mutated interleukin-34 (IL-34) polypeptides and uses thereof in therapyINST NAT SANTE RECH MED·Filed 2020·Granted Nov 11, 2025·0 cites·12 claims
- 1247US10155025B2Method for inhibiting or reducing transplant rejection by adminstration of interleukin-34INST NAT SANTE RECH MED·Filed 2015·Granted Dec 18, 2018·0 cites·7 claims
- 1346US10591465B2Methods and kits for labeling, detection and isolation of Foxp3+ regulatory T cells, isolated population of Foxp3+ regulatory T cells thus obtained and uses thereofINST NAT SANTE RECH MED·Filed 2016·Granted Mar 17, 2020·0 cites·17 claims
- 1445US2021147801A1Methods for increasing expansion and immunosuppressive capacity of a population of cd8+cd45rclow/- tregsINST NAT SANTE RECH MED·Filed 2018·Application pending·0 cites
- 1544US2021163593A1Treatment of monogenic diseases with an anti-cd45rc antibodyINST NAT SANTE RECH MED·Filed 2018·Application pending·0 cites
- 1636US2020010519A1Nuclease fusions for enhancing genome editing by homology-directed transgene integrationINST NAT SANTE RECH MED·Filed 2018·Application pending·0 cites
- 1732US2018251731A1Subpopulation of cd8+cd45rclow tregs and uses thereofINSERM INSTITUTE NATIONAL DE LA SANTE ET DE LA RECH MEDICALE·Filed 2016·Application pending·0 cites
- 1830US2017226209A1An anti-cd45rc antibody for use as drugINSERM (INSTITUT NAT DE LA SANTÉ ET DE LA RECH MÉDICALE)·Filed 2015·Application pending·0 cites
- 1928US2018015101A1Compositions and methods for antigen-specific toleranceINSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECH MÉDICALE)·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Ignacio Anegon files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →